GNPX
Genprex
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 0
EPS Beats Expectation
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About GNPX
Genprex, Inc.
A biotechnology company that develops and commercializes novel gene therapies for cancer and diabetes
3300 Bee Cave Road #650-227, Austin, Texas 78746
--
Genprex, Inc., was incorporated in Delaware in April 2009. The company is a privately held clinical-stage biopharmaceutical company developing immunogenic treatments for cancer. Genprex is a clinical-stage gene therapy company that develops a new approach to treat cancer, based on its new patented technology platform, including its original product candidate, Oncoprex Immune Gene Therapy, or Oncoprex. Their platform technology aims to treat cancer genes by encapsulating them in nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells, where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action that interrupts cell signaling pathways, causes replication and proliferation of cancer cells, re-establishes apoptosis pathways or programmed cell death pathways in cancer cells, and modulates immune responses against cancer cells. Oncoprex has also been shown to block the mechanism by which resistance develops.
Company Financials
EPS
GNPX has released its 2023 Q3 earnings. EPS was reported at -0.13, versus the expected -0.11, missing expectations. The chart below visualizes how GNPX has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
